GA-BIOLOG-ID
Biolog-id, LLC, a world leader in connected solutions for blood products, and South Texas Blood & Tissue Center, a leading provider of blood products throughout South Texas and beyond, mark three months of successful utilization of Biolog-id’s dedicated Convalescent Plasma solution in its supply chain. The deployed solution provides real-time visibility to convalescent plasma from collection to distribution, streamlining inventory, improving efficiency, and ultimately maximizing Return on Donation. Better visibility to the inventory facilitates efficient management of convalescent plasma, and so increases the availability of these scarce and valuable antibodies to the COVID-19 patients who need them.
“It was key for our team to ensure that Biolog-id’s solution could adapt to rapid changes in manufacturing, regulation, and market conditions for this unique product category,” said Elizabeth Waltman, Chief Operating Officer at South Texas Blood & Tissue Center. “Three months later we can fully appreciate how important that flexibility was for our blood center and for the COVID-19 patients that rely on us.”
“In addressing the need for a Convalescent Plasma solution, we used an inside-the-box approach to innovation,” said Amit Mayer, VP Innovation & Analytics at Biolog-id LLC. “This allowed us to leverage existing elements of our hardware, software, and industry know-how to rapidly develop a robust solution for a completely new type of blood product.”
“Our culture of collaboration meshed well with the needs of South Texas Blood & Tissue Center and their desire to positively influence patient outcomes.,” said Troy L. Hilsenroth, CEO Biolog-id LLC. “The solution we have deployed demonstrates our joint commitment to find new and better ways to track, store, and distribute high-value products in healthcare.”
About Biolog-id
Biolog-id has developed a patented smart solution for the management and traceability of sensitive, high-value health products throughout the hospital supply chain to ensure safe delivery from donor to patient. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has 90 employees worldwide. Biolog-id is owned by its founder, managers, and the Xerys Funds.
Company URL : www.biolog-id.com
About South Texas Blood & Tissue Center
The South Texas Blood & Tissue Center (STBTC) is a nonprofit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties. It is the largest blood supplier in the region. In addition, it recovers and distributes donated human tissue for transplant. STBTC has a 45-year history serving the South Texas community. It is part of the BioBridge Global
family of nonprofit organizations, which offers services in regenerative medicine and research including blood banking and resource management; cellular therapy; umbilical cord blood collection and storage; donated human tissue recovery and distribution for transplant; and testing of blood and plasma products to help patients in the United States and worldwide. STBTC has seven donor rooms in South Texas and conducts hundreds of mobile blood drives each year. STBTC is online at SouthTexasBlood.org
.
Company URL: www.southtexasblood.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005067/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom